HeXem Bio Inc.
HexemBio Inc. is dedicated to extending healthy lifespan through reversing aging with advanced stem cell therapy. They focus on creating scalable and reproducible rejuvenation therapies by accessing early development states of cells, particularly targeting aged Hematopoietic Stem Cells (HSCs). Their innovative approach involves the Yolk Sac Method for healthy Hematopoietic Stem Cells, aiming to restore HSCs’ youth and create a first-of-its-kind rejuvenation therapy. The company emphasizes their extensive research, mechanism of action, and targets, validated through animal studies, to develop therapies that promote longer, healthier, and happier lives.
Industries
Nr. of Employees
small (1-50)
HeXem Bio Inc.
Products
Rejuvenated hematopoietic stem cell therapy (preclinical candidate)
A cell‑based therapeutic approach designed to restore youthful function to hematopoietic stem cells by accessing early developmental states and applying an engineered synthetic niche; validated in animal studies and developed with a focus on scalability and reproducibility.
Rejuvenated hematopoietic stem cell therapy (preclinical candidate)
A cell‑based therapeutic approach designed to restore youthful function to hematopoietic stem cells by accessing early developmental states and applying an engineered synthetic niche; validated in animal studies and developed with a focus on scalability and reproducibility.
Services
Preclinical research and validation collaborations
Collaborative research partnerships to run preclinical studies, validate therapeutic approaches in animal models, and support mechanism-of-action studies.
Preclinical research and validation collaborations
Collaborative research partnerships to run preclinical studies, validate therapeutic approaches in animal models, and support mechanism-of-action studies.
Expertise Areas
- Hematopoietic stem cell therapy development
- Stem cell niche engineering and developmental-state reprogramming
- Preclinical validation using animal models
- Mechanism-of-action and target discovery
Key Technologies
- Stem cell reprogramming
- Engineered synthetic cell niches
- Preclinical animal models
- Bioprocess scale-up for cell therapies